Classical and new renin-angiotensin signalling in atherosclerosis

Current Signal Transduction Therapy

Volumn 7, Issue 2, 2012, Pages 111-119

  Pende, Aldo ^a   Dallegri, Franco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

(Pro)renin eceptor; Angiotensin II receptors; Angiotensin converting enzyme; Angiotensins; Atherosclerosis; Mas; Prorenin; Renin

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN[1-7]; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIVANILAL; FASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLMESARTAN; PHOSPHOLIPASE C; PRORENIN; PRORENIN RECEPTOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; RENIN INHIBITOR; TOLL LIKE RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; DRUG TARGETING; ENZYME ACTIVATION; ESSENTIAL HYPERTENSION; HEART PROTECTION; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR MECHANICS; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 84861941233     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436212800376636     Document Type: Review

References (99)

1. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264: 224-36.
2. Brown MJ. Renin: Friend or foe? Heart 2007; 93: 1026-33
3. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-19.
4. Pende A, Giacchè M, Castigliola L, et al. Characterization of the binding of the RNA-binding protein AUF1 to the human AT1 receptor mRNA. Biochem Biophys Res Commun 1999; 266: 609-14. (Pubitemid 30028715)
5. Pende A, Contini L, Sallo R, et al. Characterization of RNA-binding proteins possibly involved in modulating human AT1 receptor mRNA stability. Cell Biochem Funct 2008; 26: 493-501. (Pubitemid 351947702)
6. Daugherty A, Poduri A, Chen X, Lu H, Cassis LA. Genetic variants of the renin angiotensin system: effects on atherosclerosis in experimental models and humans. Curr Atheroscler Rep 2010; 12: 167-73.
7. Sata M, Fukuda D. Crucial role of renin-angiotensin system in the pathogenesis of atherosclerosis. J Med Invest 2010; 57: 12-25.
8. Montecucco F, Lenglet S, Gayet-Ageron A, et al. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke 2010; 41: 1394-1404.
9. Marchesi C, Paradis P, Schiffrin EL. Role of renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008; 29: 367-74.
10. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2010; 2: 247-57.
11. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-95.
12. Savoia C, Schiffrin EL. Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 15: 152-8.
13. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 2008; 302: 148-58.
14. Ji Y, Liu J, Wang Z, Liu N. Angiotensin II induces inflammatory responses partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 2009; 23: 265-76.
15. Lv J, Jia R, Yang D, Zhu J, Ding G. Candesartan attenuates angiotensin II-induced mesangial cell apoptosis via TLR4/MyD88 pathway. Biochem Biophys Res Commun 2009; 380: 81-6.
16. Jurewicz M, McDermott DH, Sechler JM, et al. Human T and natural killer cells possess a functional rennin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol 2007; 18: 1093-102. (Pubitemid 46536895)
17. Hoch NE, Guzik TJ, Chen W, et al. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 2009; 296: R208-16.
18. Crowley SD, Frey CW, Gould SK, et al. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 2008; 295: F515-24.
19. Kvakan H, Kleinewietfeld M, Qadri F, et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 2009; 119: 2904-12.
20. Brasier AR, Recinos III A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257-66. (Pubitemid 34875734)
21. Montecucco F, Pende A, Mach F. The renin-angiotensin system modulates inflammatory processes in atherosclerosis evidence from basic research and clinical studies. Mediators Inflamm 2009; Article ID 752406
22. Weir MR. Effects of renin-angiotensin system inhibition on end-organ protection: Can we do better? Clin Ther 2007; 29: 1803-24
23. Siragy HM. Evidence for benefits of angiotensin receptor blockade beyond blood pressure control. Curr Hypertens Rep 2008; 10: 261-7.
24. Sica DA. Do pleiotropic effects of hypertensive medications exist or is it all about the blood pressure? Curr Hypertens Rep 2008; 10: 415-20
25. Farquharson CA, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002; 39: 767-75. (Pubitemid 34185321)
26. Tom B, Garrelds IM, Scalbert E, et al. ACE-versus chymasedependent angiotensin II generation in human coronary arteries: a matter of efficiency? Arterioscler Thromb Vasc Biol 2003; 23: 251-6. (Pubitemid 36231936)
27. Danser AHJ, van Kats JP, Admiraal PJJ, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension 1994; 24: 37-48.
28. Hilgers KF, Kuczera M, Wilhelm MJ, et al. Angiotensin formation in the isolated rat hindlimb. J Hypertens 1989; 7: 789-98. (Pubitemid 19281812)
29. Krop M, Danser AHJ. Circulating versus tissue renin-angiotensin system : on the origin of (pro)renin. Curr Hypertens Rep 2008; 10: 112-8.
30. Nguyen G, Muller DN. The biology of the (pro)renin receptor. J Am Soc Nephrol 2010; 21: 18-23.
31. Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 2010; 50: 439-65.
32. Bader M, Ganten D. Editorial: it' s renin in the brain. Circ Res 2002; 90: 8-10.
33. Klickstein LB, Kaempfer CE, Wintroub BU. The granulocyteangiotensin system. Angiotensin I-converting activity of cathepsin G. J Biol Chem 1982; 257: 15042-6.
34. Lomez ESL, Araujo RC, Bader M, Pesquero JB, Pesquero JL. Expression and activity of tonin and kallikrein in the brain of transgenic rat line expressing human tissue kallikrein. Hypertension 2002; 39: 229-32. (Pubitemid 34165220)
35. Aguilera G, Kiss A. Regulation of the hypothalamic-pituitaryadrenal axis and vasopressin secretion. Role of angiotensin II. Adv Exp Med Biol 1996; 396: 105-12. (Pubitemid 26164392)
36. Fink GD. Long-term sympatho-excitatory effect of angiotensin II: a mechanism of spontaneous and renovascular hypertension. Clin Exp Pharmacol Physiol 1997; 24: 1-95.
37. DiBona GF. Central sympathoexcitatory actions of angiotensin II: role of type 1 angiotensin II receptors. J Am Soc Nephrol 1999; 10 (Suppl 11): S90-4.
38. Fitzsimons JT. Angiotensin, thirst, and sodium appetite. Physiol Rev 1998; 78: 583-686. (Pubitemid 28340599)
39. Navar LG, Harrison-Bernard LM, Imig JD, Cervenka L, Mitchell KD. Renal responses to AT1 receptor blockade. Am J Hypertens 2000; 13: 45S-54S. (Pubitemid 30103855)
40. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003; 93: 3-13.
41. Kumar R, Singh VP, Baker KM. The intracellular reninangiotensin system: implications in cardiovascular remodeling. Curr Opin Nephrol Hypertens 2008; 17: 168-73. (Pubitemid 351253042)
42. Cousin C, Bracquart D, Contrepas A, Nguyen G. Potential role of the (pro)renin receptor in cardiovascular and kidney diseases. J Nephrol 2010; 23: 508-13.
43. Balakumar P, Jagadeesh G. Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro)renin receptor: promising young players from the old renin-angiotensinaldosterone system. J Cardiovasc Pharmacol 2010; 56: 570-9.
44. Danser AHJ, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005; 46: 1069-76. (Pubitemid 41533004)
45. Campbell DJ. Critical review of prorenin and (pro)renin receptor research. Hypertension 2008; 51: 1259-64. (Pubitemid 351555933)
46. Ichihara A, Sakoda M, Mito-Kurauchi A, Itoh H. Activated prorenin as a therapeutic target for diabetic nephropathy. Diabetes Res Clin Pract 2008; 82: S63-6.
47. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins J. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest 1996; 98: 1966-70. (Pubitemid 26376283)
48. Campbell DJ, Karam H, Menard J, Bruneval P, Mullins JJ. Prorenin contributes to angiotensin peptide formation in transgenic rats with rat prorenin expression targeted to the liver. Hypertension 2009; 54: 1248-53.
49. Peters B, Grisk O, Becher B, et al. Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J Hypertens 2008; 26: 102-9. (Pubitemid 350301935)
50. Mercure C, Prescott G, Lacombe MJ, Silversides DW, Reudelhuber TL. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. Hypertension 2009; 53: 1062-9.
51. Itskovitz J, Rubattu S, Levron J, Sealey JE. Highest concentrations of prorenin and human chorionic gonadotropin in gestational sacs during early human pregnancy. J Clin Endocrinol Metab 1992; 75: 906-10.
52. Ramser J, Abidi FE, Burckle CA, et al. A unique exonic splice enhancer mutation in a family with X-linked mental retardation and epilepsy points to a novel role of the renin receptor. Hum Mol Genet 2005; 14: 1019-27. (Pubitemid 40575877)
53. Hirose T, Hashimoto M, Totsune K, et al. Association of (pro)renin receptor gene polymorphism with blood pressure in Japanese men: The Ohasama study. Am J Hypertens 2009; 22: 294-9.
54. Cruciat CM, Ohkawara B, Acebron SP, et al. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science 2010; 327: 459-63.
55. Cousin C, Bracquart D, Contrepas A, Corvol P, Muller L, Nguyen G. Soluble form of the (pro)renin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension 2009; 53: 1077-82.
56. Ferrario CM. ACE2: more of Ang-(1-7) or less Ang II?. ACE2: More of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens 2010; 20: 1-6
57. Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens 2010; 20: 62-8.
58. Sluimer JC, Gasc JM, Hamming I, van Goor H, et al. Angiotensinconverting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. J Pathol 2008; 215: 273-9. (Pubitemid 351956708)
59. Ingelfinger JR. Angiotensin-converting enzyme 2: implications for blood pressure and kidney disease. Curr Opin Nephrol Hypertens 2009; 18: 79-84.
60. Igase M, Kohara K, Nagai T, Miki T, Ferrario CM. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res 2008; 31: 553-9. (Pubitemid 351597510)
61. Thomas MC, Pickering RJ, Tsorotes D, et al. Genetic ACE2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res 2010; 107: 888.
62. Guo YJ, Li WH, Wu R, Xie Q, Cui L. ACE2 overexpression inhibits angiotensin II-induced monocyte chemoattractant protein-1 expression in macrophages. Arch Med Res 2008; 39: 149-54. (Pubitemid 350299617)
63. Lovren F, Pan Y, Quan A, et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol 2008; 295: H1377-84.
64. Dong B, Zhang C, Feng JB, et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 1270-6.
65. Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: a peptidase in the renin-angiotensin sytem, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther 2010; 128: 119-28.
66. Iyer SN, Ferrario CM, Chappell MC. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998; 31: 356-61.
67. Lemarié CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010; 11: 19-31.
68. Henrion D, Kubis N, Levy BI. Physiological and pathophysiological functions of the AT(2) subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension 2001; 38: 1150-7. (Pubitemid 34252821)
69. Levy BI, Benessiano J, Henrion D, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98: 418-25. (Pubitemid 26255741)
70. Mogi M, Iwai M, Horiuchi M. Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol 2007; 27: 2532-9. (Pubitemid 350158902)
71. Stoll M, Unger T. Angiotensin and its AT2 receptor: new insights in an old system. Regul Pept 2001; 99: 175-82. (Pubitemid 32522545)
72. Johren O, Dendorfer A, Dominiak P. Cardiovascular and renal function of angiotensin II type-2 receptors. Cardiovasc Res 2004; 62: 460-7. (Pubitemid 38648960)
73. Savoia C, D'Agostino M, Lauri F, Volpe M. Angiotensin type 2 receptor in hypertensive cardiovascular disease. Curr Opin Nephrol Hypertens 2011; 20: 125-32.
74. Rodrigues-Ferreira S, Nahmias C. An ATIPical family of angiotensin II AT2 receptor-interacting proteins. Trends Endocrinol Metab 2010; 21: 684-90.
75. Vongpatanasian W, Thomas GD, Schwartz R, et al. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation 2007; 115: 1020-8. (Pubitemid 46328296)
76. Sales VL, Sukhova GK, Lopez-Ilasaca MA, Libby P, Dzau VJ, Pratt RE. Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. Circulation 2005; 112: 3328-36. (Pubitemid 43739379)
77. Iwai M, Chen R, Li Z, et al. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 2005; 112: 1636-43. (Pubitemid 41324526)
78. Daugherty A, Rateri DL, Lu H, Inagami T, Cassis LA. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 2004; 110: 3849-57. (Pubitemid 40023984)
79. Steckelings UM, Larhed M, Hallberg A, et al. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol 2011; 11: 187-92.
80. Bosnyak S, Welungoda IK, Hallberg A, Alerman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the nonpeptide agonist, compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol 2010; 159: 709-16.
81. Kaschina E, Grzesiak A, Li J, et al. AT2-receptor stimulation: a novel option of therapeutic interference with the renin-angiotensinsystem in myocardial infarction? Circulation 2008; 118: 2523-32.
82. Rompe F, Artuc M, Hallberg A, et al. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 2009; 55: 924-31.
83. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370: 591-603. (Pubitemid 47247855)
84. Dupont AG, Brouwers S. Brain angiotensin peptides regulate sympathetic tone and blood pressure. J Hypertens 2010; 28: 1599-1610.
85. Reaux-Le Goazigo A, Iturrioz X, Fassot C, Claperon C, Roques BP, Llorens-Cortes C. Role of angiotensin III in hypertension. Curr Hypertens Rep 2005; 7: 128-34. (Pubitemid 40803409)
86. Speth RC, Karamyan VT. The significance of brain aminopeptidases in the regulation of the actions of angiotensin peptides in the brain. Heart Fail Rev 2008; 13: 299-309.
87. Wright JW, Bechtolt AJ, Chambers SL, Harding JW. Angiotensin III and IV activation of the brain AT1 receptor subtype in cardiovascular function. Peptides 1996; 17: 1365-71. (Pubitemid 27016349)
88. Wang HX, Zhang QF, Zeng XJ, Wang W, Tang CS, Zhang LK. Effects of angiotensin III on protein, DNA, and collagen synthesis of neonatal cardiomyocytes and cardiaca fibroblasts in vitro. J Cardiovasc Pharmacol Ther 2010; 15: 393-402.
89. Zhou Q, Gensch C, Liao JK. Rho-associated coiled-coil-form kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease. Trends Pharmacol Sci 2011; 32: 167-73.
90. Cat AND, Touyz RM. Cell signaling of angiotensin II on vascular tone: novel mechanisms. Curr Hypertens Rep 2011; 13: 122-8.
91. Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol 2010; 7: 637-47.
92. Shimokawa H, Takeshita A. Rho-kinase is an important theraputic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-75. (Pubitemid 41243442)
93. Shimokawa H, Morishige K, Miyata K, et al. Long-term inhibition of Rho-kinase induces a regression of atherosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res 2001; 51: 169-77. (Pubitemid 32523066)
94. Mallat Z, Gojova A, Sauzeau V, et al. Rho-associated protein kinase contributes to early atherosclerotic lesion formation in mice. Circ Res 2003; 93: 884-8. (Pubitemid 37363063)
95. Nohria A, Grunert ME, Rikitake Y, et al. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease. Circ Res 2006; 99: 1426-32. (Pubitemid 44949679)
96. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203: 325-30.
97. Di A, Malik AB. TRP channels and the control of vascular function. Curr Opin Pharmacol 2010; 10: 127-32.
98. Inoue R, Jensen LJ, Shi J, et al. Transient receptor potential channels in cardiovascular function and disease. Circ Res 2006; 99: 119-31. (Pubitemid 44297035)
99. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16-29. (Pubitemid 351664943)